June 13 - 16, 2022


San Diego, CA

Visit with us at Booth 1011


past Events

May 16 - 19, 2022

ASGCT 2022

Washington, DC

Visit with us at Booth 160

ASGCT logo

May 9 - 12, 2022


Boston, MA

Visit with us at Booth 107

2022 04 18 TIDES 2022 Logo white

May 4 - 7, 2022


San Francisco, CA

Visit with us at Booth 107


March 7th-10th


Join us for a presentation on March 9th at 12:30pm, “High-Throughput platforms for Gene Therapy Programs”, Presented by Patrick Starremans, PhD is Director of Analytical Development and Head of Resilience’s Gene-therapy AD-group.

Key topics to be presented on: 

  • Future-proofing your gene therapy
  • Forward-thinking in process development including an introduction to new platforms and technology modules
  • Fit for purpose design
  • High throughput process and analytical development concepts
  • How partnering with Resilience will change the way you consider service providers and industry partners

Anytime during the week, stop by our booth (#19) to learn how we can help you by revolutionizing the way medicines are made.

Rare therapies resilience
Patrick Starremans - Headshot-2

Patrick Starremans, Ph.D.

Resilience, Director of Analytical Development and Head of Resilience’s Gene-therapy AD-group

Patrick Starremans, PhD is Director of Analytical Development and head of Resilience’s Gene-therapy AD-group. Dr. Starremans received his PhD in Medical Sciences and Master’s in Medical Biology from the Radboud University in Nijmegen the Netherlands and an undergraduate degree in Biochemistry from Zuyd University of Applied Sciences. Following his move to the US, his career focused on molecular and cell-based assay development for the past 18 years, starting at Harvard Medical School and followed by tenures in pharmacology at Genzyme, Sanofi, Evotec and Mitobridge followed by a switch to Gene Therapy Analytical Development when he joined Voyager Therapeutics as head of Process Analytics and later as head of Analytical Development building out their CMC-Analytical capabilities and infrastructure and helping Voyager file their first successful IND for an internal program.

January 25th-28th

Advanced Therapies Week 2022

Miami Beach Convention Center

Join us for a panel discussion on January 27th at 12:30pm, “Technology, Disruptive Innovation and Partnerships that are revolutionizing How Medicines Are Made“, moderated by our very own David DiGiusto, CTO of Cell and Gene Therapy. Panelists will include an array of industry experts including Resilience team members: Bruce Thompson., VP & Technical Lead, Cell Therapy and John Kerwin, Senior Director & Technical Head, Gene Therapy.

The technology of manufacturing complex medicines like cell and gene therapy hasn’t kept pace with the wave of scientific discoveries fueling them. Because many of these approaches to attacking diseases are so new, the process of making them hasn’t progressed beyond methods only meant for small batch, academic labs. In this panel discussion, we will take a deeper look into what has hindered growth and scalability of these medicines, and how disruptive technology and cross-industry partnerships are driving change in this young and exciting field of medicine.

Key topics:

  • Best practices for successful partnerships between industry, clients, service providers, technology partners, and academia
  • Viral vaccine technology platforms
  • Investment and risk-sharing in development
  • Product life cycle management

Anytime during the week, stop by our booth (#201) to learn how we can help you by revolutionizing the way medicines are made.

Advanced Therapies Week
David Digiusto

David DiGiusto, PH.D

Resilience, Chief Technology Officer, Cell & Gene Therapy

David DiGiusto PhD is formally trained as an immunologist and stem cell biologist with over 20 years of academic and 12 years of industrial experience in translational medicine with a focus on Cell and Genetic therapies. Dr. DiGiusto has made significant contributions to product development and manufacturing for more than a dozen Phase I/II clinical trials. He has led the creation and/or operation of 11 GMP compliant biologics manufacturing facilities including the oversight of process development, manufacturing, quality systems, and regulatory affairs infrastructure. Under his direction, plasmid DNA, CAR T-cells, regulatory T-cells, engineered stem cell grafts, gene modified hematopoietic stem cell and ES derived cell therapy products have been developed, manufactured and used in first in human and early stage clinical investigations. Dr. DiGiusto is the former North American Vice President for ISCT (2016-2018), former member of the NIH recombinant DNA advisory committee (RAC) and an independent biotechnology consultant (>30 years). He received his undergraduate and Ph.D. degrees from the University of Colorado.

Join Us

We’re constantly looking for builders, creatives, and innovators who want to make big change and serve an important mission.